Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

According to a Phase 3 trial published in The Lancet Diabetes & Endocrinology, a once-weekly combination of semaglutide and ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure.

Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Indian drugmaker, Cipla Ltd, sees GLP-1 drugs, used to treat type-2 diabetes and obesity, as a significant new therapy opportunity in the Indian market.

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.